Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 360 results:
Συντάκτης Τίτλος Τύπος [ Έτος] Φίλτρα: Συντάκτης is Polyzos, Stergios A [Clear All Filters]
(2017).
Activin A and follistatin in patients with nonalcoholic fatty liver disease..
Metabolism. 65(10), 1550-8.
(2016). Adipokines in nonalcoholic fatty liver disease..
Metabolism. 65(8), 1062-79.
(2016). Adiponectin as a target for the treatment of nonalcoholic steatohepatitis with thiazolidinediones: A systematic review..
Metabolism. 65(9), 1297-306.
(2016). Circulating follistatin displays a day-night rhythm and is associated with muscle mass and circulating leptin levels in healthy, young humans..
Metabolism. 65(10), 1459-65.
(2016). Circulating leptin in non-alcoholic fatty liver disease: a systematic review and meta-analysis..
Diabetologia. 59(1), 30-43.
(2016). Circulating sclerostin and Dickkopf-1 levels in patients with nonalcoholic fatty liver disease..
J Bone Miner Metab. 34(4), 447-56.
(2016). Clinical vertebral fractures following denosumab discontinuation..
Endocrine. 54(1), 271-272.
(2016). Colchicine to decrease inflammation and fibrosis in patients with metabolic dysregulation..
Med Hypotheses. 95, 34.
(2016). Emerging and future therapies for nonalcoholic steatohepatitis in adults..
Expert Opin Pharmacother. 17(14), 1937-46.
(2016). Fetuin-A levels and free leptin index are reduced in patients with chronic lymphocytic leukemia: a hospital-based case-control study..
Leuk Lymphoma. 57(3), 577-84.
(2016). Helicobacter pylori infection and oesophageal adenocarcinoma..
Cancer Epidemiol. 42, 206-7.
(2016). Homocysteine in nonalcoholic steatohepatitis: A reply..
Eur J Intern Med. 35, e40-e41.
(2016). Letter to the Editor: Bone Turnover as a Potential Determinant of Bone Mineral Density Increase Following the Transition From Bisphosphonates to Either Denosumab or Zoledronic Acid..
J Clin Endocrinol Metab. 101(9), L89-90.
(2016). Nonalcoholic fatty future disease..
Metabolism. 65(8), 1007-16.
(2016). Periostin on the road to nonalcoholic fatty liver disease..
Endocrine. 51(1), 4-6.
(2016). A potential impact of Helicobacter pylori infection on minimal hepatic encephalopathy pathobiology..
J Gastrointestin Liver Dis. 25(3), 405-6.
(2016). Potential impact of Helicobacter pylori-related human β-defensin-1 on hepatic encephalopathy and neurodegeneration..
Ann Gastroenterol. 29(1), 99.
(2016). Potential molecular aspects of Helicobacter pylori-related hyperplastic polyp development and progression..
Eur J Gastroenterol Hepatol. 28(7), 851-2.
(2016). Prevalence and determinants of type 2 diabetes mellitus in a Greek adult population..
Hormones (Athens). 15(1), 88-98.
(2016).
(2016).
(2016). Association between circulating irisin and homocysteine in patients with nonalcoholic fatty liver disease..
Endocrine. 49(2), 560-2.
(2015). Association between cirrhosis and Helicobacter pylori-related brain pathologies..
Eur J Gastroenterol Hepatol. 27(2), 183.
(2015).
(2015).